Among the total, six phase 3 RCTs that investigated a PD-1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment for advanced nonsquamous (NSQ) NSCLC were identified: CameL (19), CheckMate 227 Part 2 (20), EMPOWER Lung-3 (21), KEYNOTE-189 (22), CHOICE-01 (23), and RATIONALE 304 (24) (Table 3). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.